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Objective: Tuberculosis (TB) is an important opportunistic infection in HIV patients.
Immune responses toMycobacterium tuberculosis in HIV/TB patients were evaluated.
Methods: Fifteen patients with HIV/TB, ten with HIV, four with TB, and five controls
were enrolled. Peripheral blood mononuclear cells were isolated and stimulated with
mycobacterial antigen (PPD). Interferon (IFN)-g and TNF-a in culture supernatants
were measured by ELISA.
Results: IFN-g and TNF-a production after PPD stimulation was markedly decreased in
HIVpatients, butnot inHIV/TBpatients. InHIVpatientswithaCD4cell countof less than
200/mm3, IFN-g and TNF-a production after PPD stimulation was higher in HIV/TB
patients than in HIV patients. Cytokine responses toM. tuberculosis reconstituted after
highly active antiretroviral therapy (HAART) and were prominent in HIV/TB patients.
Conclusions: Cytokine responses to M. tuberculosis were retained in HIV-infected
patients with tuberculosis, even in patients with a CD4 cell count of less than 200/
mm3, and reconstituted after HAART.
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Tuberculosis (TB) is one of the most common oppor-
tunistic infections in human immunodeficiency virus
type 1 (HIV-1)-infected patients.1,2 The production
of interferon (IFN)-g and tumor necrosis factor
(TNF)-a appears to be crucial in the control of
TB.3,4 Moreover, the impaired production of IFN-g
correlates with the progression of immunodefi-
ciency.5 Understanding the biology of IFN-g produc-
tion and responsiveness among HIV-1 infected
patients with TB (HIV/TB) is important because this
cytokine may have a predominant protective role in
TB infection, and it is emerging as a possible immu-
notherapeutic agent for patients with hard-to-treat
TB.3,6 In addition, the cellular production of TNF-a
may be particularly important, as this cytokine is
produced in response to mycobacterial products, is
synthesized at elevated levels in active tuberculo-
sis, and is important in granuloma formation.4
Host immune responses to TB during its develop-
ment in HIV patients, especially during highly active
antiretroviral treatment (HAART), are not fully
understood. Therefore, cellular immune responses
against Mycobacterium tuberculosis in HIV patients
with tuberculosis were evaluated.Materials and methods
Subjects
Thirty-four individuals (31 males, three females)
were enrolled in this study. The study population
was divided into four groups: HIV-1 infected patients
with TB (HIV/TB), HIV-1 infected patients (HIV), TB
patients (TB), and normal subjects.
Definition
TB patients were classified as definite, probable and
possible cases. Definite cases were defined as cases
from whichM. tuberculosis had been isolated. Prob-
able cases were defined as acid-fast bacilli smear
positive cases with symptoms and radiographic find-
ings consistent with tuberculosis. Cases with patho-
logic findings compatible with tuberculosis, such as
granuloma and caseation necrosis were also defined
as probable cases. Possible cases were defined as
cases with symptoms and radiological findings com-
patible with tuberculosis, and whose symptoms and
radiological findings improved after anti-TB medi-
cation. HIV infection was diagnosed by ELISA and
confirmed by Western blot. The control group was
composed of BCG-vaccinated, healthy individuals
who had no previous history of TB, and who werealso seronegative for HIV. All HIV-infected patients
were also BCG-vaccinated in their childhood as part
of the routine vaccination schedule.
Cell culture
Peripheral blood mononuclear cells (PBMCs) were
isolated from 15 ml of whole blood by centrifugation
through a Ficoll-Paque separation (Amersham Phar-
macia Biotech, Sweden). PBMCs were resuspended
(5  106 cells/ml) in RPMI 1640 with glutamate
(2 mM), penicillin and streptomycin (1 U/ml and
100 mg/ml, respectively), 20 mM HEPES, and 10%
(vol/vol) heat-inactivated human albumin. Assays
were performed with 2.5  105 cells/well in a 96-
well plate. Cells were stimulated with a purified
protein derivative (PPD; Statens Seruminstitute,
Denmark). Phytohemagglutinin (PHA; Sigma, USA)
was used as a positive control. Cell cultures were
maintained at 37 8C in 5% CO2, and culture super-
natants were harvested after 72 h of PHA stimula-
tion, and after 120 h of PPD stimulation.
Supernatants were stored at 70 8C for IFN-g and
TNF-a measurement.
Measurement of IFN-g and TNF-a
IFN-g and TNF-a levels in culture supernatants were
determined using commercial ELISA kits (Quanti-
kine, R&D Systems, Inc. USA), in accordance with
the manufacturers’ instructions.
Statistical analysis
Nonparametric methods, namely, the Mann-Whitney
U test or the Wilcoxon signed rank test were used to
compare continuous variables. All P values were
two-tailed, and P < 0.05 was considered to indicate
statistical significance. SPSS (version 10.0) software
was used for the analysis.Results
Demographic characteristics
Thirty-four subjects were enrolled in this study
between January 2000 and April 2002. Of these,
15 patients had HIV/TB infection, ten had HIV infec-
tion, four had TB, and five were healthy HIV-sero-
negative subjects. Of the 15 HIV/TB patients, three
had proven TB, eight had probable TB, and four had
possible TB. Of the four TB patients, three were
proven cases and one was a probable case. Clinical
characteristics of patient groups are shown in
Table 1. Median CD4 cell count (per microliter)
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Table 1 Clinical characteristics of study population.
Characteristic Patient group
HIV/TB (n = 15) HIV (n = 10) TB (n = 4)
Age, median years (range) 39 (25—60) 39 (30—65) 52 (41—64)
Male sex, no. (%) 14 (93.3) 9 (90) 3 (75)
CD4 cell count, no. (%)
<200 CD4 cells/mL 8 (53.3) 6 (60) 0
200—500 CD4 cells/mL 7 (46.7) 4 (40) 0
>500 CD4 cells/mL 0 0 4 (100)
Values not otherwise identified are no. (%) of patients.was 160 in HIV/TB patients and 145 in HIV patients,
which was not significantly different (P = 0.781,
Mann-Whitney U test).
IFN-g and TNF-a production by PHA or PPD
IFN-g and TNF-a levels after PHA stimulation were
not different in the four groups (Table 2). The
median IFN-g level after PPD stimulation was sig-
nificantly higher in HIV/TB patients (1555 pg/ml;
347 and 3059 pg/ml for the 25th and 75th quartiles,
respectively) than in HIV patients (0 pg/ml; 0 and
204 pg/ml for the 25th and 75th quartiles, respec-
tively; P < 0.001, Mann-Whitney U test). Also, the
median TNF-a level after PPD stimulation was
higher in HIV/TB patients (562 pg/ml; 190 and
1620 pg/ml for the 25th and 75th quartiles, respec-
tively) than in HIV patients (132 pg/ml; 55 and
240 pg/ml for the 25th and 75th quartiles, respec-
tively; P = 0.013, Mann-Whitney U test). IFN-g and
TNF-a levels after PPD stimulation were not signifi-
cantly different in the HIV/TB, TB, and control
groups (Table 2). Further stratification of IFN-g
and TNF-a levels by CD4 cell count in HIV/TB
patients is shown in Figure 1. In the eight HIV/TB
patients with a CD4 cell count of less than 200/mm3,
the median level of IFN-g after PPD stimulation was
1139 pg/ml (187 and 2636 pg/ml for the 25th and
75th quartiles, respectively), which was higher than
that of HIV patients (0 pg/ml; 0 and 204 pg/ml forTable 2 Cytokine responses induced by mycobacterial antig
TB, and control subjects.
HIV/TB (n = 15) H
IFN-g (pg/ml) after PHA stimulation 767 (72 & 2860) 3
IFN-g (pg/ml) after PPD stimulation 1555* (347 & 3059)
TNF-a (pg/ml) after PHA stimulation 765 (225 & 1677) 3
TNF-a (pg/ml) after PPD stimulation 562y (190 & 1620) 1
Data are presented as median value (25th and 75th quartiles, resp
* P = 0.001, when comparedwith levels of IFN-g after PPD stimulat
control subjects by Mann-Whitney U test.
y P = 0.013, when compared with levels of TNF-a after PPD stimu
with control subjects by Mann-Whitney U test.the 25th and 75th quartiles, respectively; P = 0.003,
Mann-Whitney U test). The median level of TNF-a
after PPD stimulation was also higher in HIV/TB
patients than in HIV patients (575 vs. 132 pg/ml;
P = 0.004).
Furthermore, the median IFN-g level after PPD
stimulation was significantly lower in HIV patients
(0 pg/ml; 0 and 204 pg/ml for the 25th and 75th
quartiles, respectively) than that in normal control
(1519 pg/ml; 821 and 1752 pg/ml for the 25th and
75th quartiles, respectively; P < 0.001, Mann-Whit-
ney U test) (Table 1).
Changes of IFN-g and TNF-a production
during HAART
Five HIV patients and six HIV/TB patients on highly
active antiretroviral treatment (HAART) were pro-
spectively monitored for IFN-g and TNF-a measure-
ment. The HIV/TB patients also received anti-TB
medication together with HAART. During a six-month
period of HAART, all patients except two showed
increased CD4 cell counts. In HIV patients, initial
mean CD4 cell count increased significantly after six
months (72  61 cells/mm3 vs. 174  104 cells/
mm3, P = 0.043, Wilcoxon signed rank test). But in
HIV/TB patients, the observed increase of mean CD4
cell counts was not significant (174  115 cells/
mm3, 242  176 cells/mm3, P = 0.345, Wilcoxon
signed rank test).en (PPD) and mitogen (PHA) in patients with HIV/TB, HIV,
IV (n = 10) TB (n = 4) Control (n = 5)
93 (0 & 1398) 323 (79 & 569) 292 (116 & 1020)
0 (0 & 204) 1587 (1550 & 2034) 1519 (821 & 1752)
16 (104 & 492) 351 (108 & 609) 579 (196 & 1925)
32 (55 & 240) 379 (211 & 644) 265 (154 & 494)
ectively).
ion in HIV-infected patients, and P = 0.861, when comparedwith
lation in HIV-infected patients, and P = 0.206, when compared
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Figure 1 Production of IFN-g (a) and TNF-a (b) by
mycobacterial antigen. 1. Control (n = 5); 2. TB patients
(n = 4); 3. HIV patients (n = 10); 4. HIV/TB patients with a
CD4 cell count  200/mm3 (n = 8); 5. HIV/TB patients with
a CD4 cell count > 200/mm3 (n = 7).Although IFN-g and TNF-a levels after PHA sti-
mulation increased in HIV patients after HAART in
parallel with increasing CD4 cell count, the recovery
of cytokine responses by PPD stimulation was not
prominent, except in one patient whose CD4 cell
count recovered to 320/mm3 (Figure 2, panel I). In
HIV patients, the increased median IFN-g level after
PPD stimulation was not significant (0 pg/ml; 0 and
707 pg/ml for the 25th and 75th quartiles, respec-
tively, and 987 pg/ml; 615 and 1294 pg/ml for the
25th and 75th quartiles, respectively; P = 0.08, Wil-
coxon signed rank test). The increased median TNF-
a level after PPD stimulation was also not significant
(0 pg/ml; 0 and 84 pg/ml for the 25th and 75th
quartiles, respectively, and 91 pg/ml; 10 and
774 pg/ml for the 25th and 75th quartiles, respec-
tively; P = 0.068, Wilcoxon signed rank test).In HIV/TB patients, the median IFN-g level after
PPD stimulation significantly increased (755 pg/ml;
352 and 2145 pg/ml for the 25th and 75th quartiles,
respectively, and 1998 pg/ml; 818 and 3801 pg/ml
for the 25th and 75th quartiles, respectively;
P = 0.028, Wilcoxon signed rank test). However,
increased median TNF-a level after PPD stimulation
was not significant (378 pg/ml; 129 and 1217 pg/ml
for the 25th and 75th quartiles, respectively, and
552 pg/ml; 353 and 880 pg/ml for the 25 and 75
quartiles, respectively; P = 0.345, Wilcoxon signed
rank test). IFN-g and TNF-a responses to PPD sti-
mulation were retained in HIV/TB patients, even in
patients with CD4 cell count of less than 200/mm3,
and these response were sustained during the
HAART period (Figure 2, panel II).Discussion
In the present study, cytokine responses were com-
pared against mycobacterial antigen in four groups,
namely, HIV, HIV/TB, TB, and a normal subject
group. Proliferative responses to mycobacterial
antigen in HIV patients were less vigorous than in
normal subjects, even when the CD4 cell count was
greater than 200/mm3 in HIV patients. These results
suggest that HIV patients are susceptible to M.
tuberculosis infection, even when the CD4 cell
count exceeds 200/mm3. Indeed, a previous study
showed that 18% (8/44) of HIV patients with tuber-
culosis had CD4 cell counts greater than 200/mm3.7
In contrast, IFN-g and TNF-a production induced by
mycobacterial antigens was retained in HIV patients
with TB, even when their CD4 cell counts were less
than 200/mm3. Wallis et al. also reported that
production of TNF-a was three to ten times greater
in HIV-1 infected patients with pulmonary tubercu-
losis than in controls.8
The increased IFN-g and TNF-a production in
HIV patients with TB, compared with HIV patients
without TB, might be due to the activation of
cellular immune responses in an attempt to control
the M. tuberculosis infection. Mayanja-Kizza et al.
showed that there was a marked variability in M.
tuberculosis-stimulated IFN-g production in HIV
patients with tuberculosis and that this was related
to the degree of immunodeficiency.6 Several stu-
dies have reported a low level of IFN-g production
in HIV patients with tuberculosis, but the majority
of these studies examined the dually infected
patients as a group, regardless of individual CD4
cell status,9,10 or the patients enrolled had severe
tuberculosis, with frequent extrapulmonary disse-
mination.11 Sodhi et al. reported that the radio-
graphic extent of disease and the site of disease
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Figure 2 Effect of HAART on the expression of IFN-g and TNF-a by PHA and PPD stimulation in HIV-infected patients
without tuberculosis (I) and with tuberculosis (II). Panel I. Initial mean CD4 cell count increased significantly after six
months of HAART (72  61 cells/mm3, 174  104 cells/mm3, P = 0.043, Wilcoxon signed rank test). Although IFN-g and
TNF-a levels after PHA stimulation increased in parallel with the CD4 cell count, the recovery of cytokines response to
PPD stimulation was not prominent except in patient 5 whose CD4 cell count had recovered to 320/mm3. Panel II. The
increased mean CD4 cell count was not significant (174  115 cells/mm3, 242  176 cells/mm3, P = 0.345, Wilcoxon
signed rank test). However, the expression of IFN-g and TNF-a after PPD stimulation was retained, and in particular IFN-g
levels were markedly increased after six months. A. IFN-g response to PHA stimulation; B. IFN-g response to PPD
stimulation; C. Change of CD4 cell count during the HAART period; D. TNF-a response to PHA stimulation; E. TNF-a
response to PPD stimulation.were the only independent predictors of IFN-g
production in HIV-negative and in HIV-infected
patients, suggesting that reduced IFN-g production
by PBMCs is a marker of severe tuberculosis regard-
less of HIV seropositivity.12 Some HIV/TB patients
with CD4 cell counts of more than 200 cells/mm3
retained the ability to produce IFN-g in response to
mycobacterial antigens.12 In the present study, it isnoted that cytokine responses against M. tubercu-
losis were retained in HIV-infected patients with
tuberculosis, even in patients with CD4 cell counts
of less than 200/mm3. However, the difference
between this report and others with respect to
the preservation of PPD-induced IFN-g responses
in HIV/TB cases may reflect differences in CD4
count.
Cytokine responses induced by Mycobacterium tuberculosis 115Although only four TB patients without HIV were
available, this study shows that low levels of myco-
bacterial antigen-induced IFN-g and TNF-a have not
been found in TB patients. These results are consis-
tent with those of Surcel et al. in this regard. These
workers showed that the number of IFN-g secreting
cells was not depressed in active TB patients.13
Silveira et al. also suggested that there was no
down-regulation of IFN-g production in active pul-
monary TB patients in Portugal.14 However, another
study demonstrated that IL-2 and IFN-g expression
was depressed when PBMCs were stimulated with
mycobacterial antigens in tuberculosis patients.15
Possible explanations for these discrepancies among
studies include the difference in the prevalence of
the latent infection with tuberculosis or the BCG
vaccination rate among the study population. Since
South Korea is an endemic area for tuberculosis, the
majority of the population receive the BCG vaccina-
tion routinely.16,17 A recent nationwide tuberculosis
prevalence survey in South Korea demonstrated that
observed tuberculin positivity (10 mm in diameter)
in subjects aged under 30 was 15.5%, that the pre-
valence of active pulmonary tuberculosis was
approximately 1%, and that the BCG scar prevalence
of subjects aged under 30 was 91.8%.17 The high
prevalence of latent infection or exposure to M.
tuberculosis prior to HIV infection may contribute
to thepreserved immune response toM. tuberculosis
in the patients in the present study.
Mycobacterium tuberculosis infection results in
the activation of T cells and macrophages, which
may harbor latent HIV. This activation is beneficial
to the host immunity to mycobacterial disease, but
it may result in a reactivation of latent HIV. There is
a report which found that the production of TNF-a
and the mean b2-microglobulin level were greater
in HIV-1 seropositive patients with pulmonary tuber-
culosis.8 These observations suggest that HIV-1-
associated tuberculosis is accompanied by immune
activation that may result in increased HIV replica-
tion and accelerated progression to AIDS.8
The restoration of lymphocytes responses to
mycobacterial antigens by HAARTwas first reported
by Autran et al.18 It was demonstrated that cell-
mediated immune responses to Mycobacterium
avium reconstituted rapidly after HAART, and that
this was sustained even with partial viral suppres-
sion.19 In HIV-infected patients receiving HAART,
primary and secondary prophylaxis against Pneumo-
cystis carinii pneumonia can be safely discontinued
after the CD4 cell count has increased to more than
200/mm3 for more than three months.20 HAARTalso
restored immune responses to M. tuberculosis,
although this restoration was found to be delayed
and did not reach the levels seen in healthy, HIV-negative control subjects.21 Indeed, one cohort
study found that HAART reduced the incidence of
HIV-associated tuberculosis by more than 80% in an
area endemic with tuberculosis and HIV.22
The results of this study suggest that the cellular
immune responses of HIV-infected patients with/
without tuberculosis recovered as the CD4 cell count
increased during the HAART period. In HIV-infected
patients without tuberculosis, the IFN-g and TNF-a
production by PPD was not as prominent as that
induced by PHA stimulation. In HIV-infected patients
with tuberculosis, IFN-g and TNF-a production after
PPD stimulation were retained and sustained during
the HAART period. The relative lack of reconstitu-
tion of PPD-induced IFN-g responses in HIV patients
might be due to relative lack of increment of CD4
cell count. Indeed, in a patient with an improved
CD4 cell count of 320/mm3 after HAART, IFN-g and
TNF-a levels after PPD stimulation were found to be
similar to those after PHA stimulation.
The differences in recovery of immune responses
between HIVonly and dually infected subjects might
also reflect a different level of exposure to the
antigen. Therefore it would have been informative
to see whether there is a similar or a different trend
in the recovery of responses to non-TB antigens, to
which both populations had a similar exposure.
In conclusion, cytokine responses against M.
tuberculosis were retained in HIV-infected patients
with tuberculosis, even in patients with a CD4 cell
count of less than 200/mm3. Cytokine responses to
M. tuberculosis reconstituted after HAART, and
were prominent in HIV/TB patients.Acknowledgements
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